Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7465-7470

  Shields, Ryan K ^a,b   Nguyen, M Hong ^a,b   Press, Ellen G ^a   Cumbie, Richard ^a   Driscoll, Eileen ^a   Pasculle, A William ^a   Clancy, Cornelius J ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; FKS1 PROTEIN; FKS2 PROTEIN; FUNGAL PROTEIN; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; LIPOPEPTIDE; MICAFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FKS1 GENE; FKS2 GENE; FUNGAL GENE; FUNGUS MUTATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ANTIFUNGAL RESISTANCE; BLOOD; CANDIDA GLABRATA; CANDIDIASIS; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION RATE; PATHOGENICITY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MUTATION RATE;

EID: 84946794390     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01973-15     Document Type: Article

References (30)

1. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. 2014. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 59:819-825. http://dx.doi.org/10.1093/cid /ciu407.
2. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
3. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. Presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 56: 4862-4869. http://dx.doi.org/10.1128/AAC.00027-12.
4. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. 2014. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 20:1833-1840.
5. Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, Mathisen MS. 2015. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 70:2362-2368. http://dx.doi.org/10.1093/jac /dkv087.
6. Shields RK, Nguyen MH, Press EG, Updike CA, Clancy CJ. 2013. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 57:3528-3535. http://dx.doi.org/10.1128/AAC.00136-13.
7. Shields RK, Nguyen MH, Press EG, Clancy CJ. 2014. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 58:7601-7605. http://dx.doi.org/10.1128/AAC.04134-14.
8. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133-163. http: //dx.doi.org/10.1128/CMR.00029-06.
9. Perlin DS. 2014. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs 74:1573-1585. http://dx.doi.org/10.1007/s40265-014-0286-5.
10. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts, fourth informational supplement M27-S4, 4th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G. 2013. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141-160. http://dx.doi.org/10.1111/j.1469-0691.2011.03703.x.
12. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 57:5836-5842. http://dx.doi.org/10.1128 /AAC.01519-13.
13. Kartsonis N, Killar J, Mixson L, Hoe C-M, Sable C, Bartizal K, Motyl M. 2005. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 49:3616-3623. http: //dx.doi.org/10.1128/AAC.49.9.3616-3623.2005.
14. Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. 2014. Realworld experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother 58:1897-1906. http://dx.doi.org/10.1128/AAC.02163-13.
15. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369-11.
16. Espinel-Ingroff A, Alvarez-Fernandez M, Canton E, Carver PL, Chen SC, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadis J, Morris AJ, Pelaez T, Quindos G, Rodriguez-Iglesias M, Sanchez-Reus F, Shoham S, Wengenack NL, Borrell Sole N, Echeverria J, Esperalba J, Gomez GDLPE, Garcia Garcia I, Linares MJ, Marco F, Merino P, Peman J, Perez Del Molino L, Rosello Mayans E, Rubio Calvo C, Ruiz Perez de Pipaon M, Yague G, Garcia-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, Turnidge J. 17 August 2015. A multi-center study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin and micafungin using the Sensititre(R) YeastOne colorimetric method. Antimicrob Agents Chemother.
17. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 54:2655-2659. http://dx.doi.org/10.1128/AAC.01711-09.
18. Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN, Pfaller MA. 2013. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother 58:577-580.
19. Shor EPDS. 2015. Coping with stress and the emergence of multidrug resistance in fungi. PLoS Pathog 11:e1004668. http://dx.doi.org/10.1371 /journal.ppat.1004668.
20. Arendrup MC, Perlin DS. 2014. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 27:484-492. http://dx.doi.org/10.1097/QCO.0000000000000111.
21. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. 2013. Anidulafungin and micafungin minimum inhibitory concentration breakpoints are superior to caspofungin for identifying FKS mutant Candida glabrata and echinocandin resistance. Antimicrob Agents Chemother 57:6361-6365. http://dx.doi.org/10.1128/AAC.01451-13.
22. Arendrup MC, Rodriguez-Tudela JL, Lass-Florl C, Cuenca-Estrella M, Donnelly JP, Hope W. 2011. EUCAST technical note on anidulafungin. Clin Microbiol Infect 17:E18-E20. http://dx.doi.org/10.1111/j.1469-0691.2011.03647.x.
23. Healey KR, Katiyar SK, Raj S, Edlind TD. 2012. CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol Microbiol 86:303-313. http://dx.doi.org/10.1111/j.1365-2958.2012.08194.x.
24. Walker LA, Gow NA, Munro CA. 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother 57:146-154. http://dx.doi.org/10.1128/AAC.01486-12.
25. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199-1203. http://dx.doi.org/10.1128 /JCM.06112-11.
26. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, Schaffner W, Beldavs ZG, Chiller TM, Park BJ, Cleveland AA, Lockhart SR. 2014. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690-4696. http://dx.doi.org/10.1128/AAC.03255-14.
27. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg B, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org /10.1086/596757.
28. Eschenauer GA, Nguyen MH, Clancy CJ. 2015. Is fluconazole or an echinocandin the agent of choice for candidemia. Ann Pharmacother 49: 1068-1074. http://dx.doi.org/10.1177/1060028015590838.
29. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):S19-S37.
30. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54:1110-1122. http://dx.doi.org/10.1093/cid/cis021.